Primary glial tumor patients treated by combining cis-platin and etoposide

A. Boiardi, A. Silvani, I. Milanesi, M. Botturi, G. Broggi

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Thirty eight patients with malignant gliomas (27 GBM and 11 AA) were treated with up to 7 cycles of CDDP + VP16 every month after surgery. Chemotherapy was planned as two cycles before and 5 cycles after radiation (42 Gy) using a three times daily fractionation schedule. No severe toxicity was observed. The object of our study was to investigate the antitumor effectiveness by combining CDDP plus VP16 against primary malignant glial tumors. The time to tumor progression (TTP) and survival time (ST) of the GBM patients in the present study were 38.5 and 68,5 weeks respectively. The TTP of the AA patients was 73 weeks and the ST was not calculated as most patients are still alive. By the 18th. month after surgery, 38% of GBM and 74% of AA patients treated with (CDDP + VP16) are still alive. This study demonstrates that the combination of CDDP and VP16 is effective in patients with malignant gliomas.

Original languageEnglish
Pages (from-to)165-170
Number of pages6
JournalJournal of Neuro-Oncology
Volume11
Issue number2
DOIs
Publication statusPublished - 1991

Fingerprint

Etoposide
Neuroglia
Neoplasms
Glioma
Radiation Dosage
Survival
Appointments and Schedules
Drug Therapy

Keywords

  • chemotherapy
  • cis-platin
  • etoposide
  • glioma
  • survival-time

ASJC Scopus subject areas

  • Cancer Research
  • Clinical Neurology
  • Oncology
  • Neurology
  • Neuroscience(all)

Cite this

Primary glial tumor patients treated by combining cis-platin and etoposide. / Boiardi, A.; Silvani, A.; Milanesi, I.; Botturi, M.; Broggi, G.

In: Journal of Neuro-Oncology, Vol. 11, No. 2, 1991, p. 165-170.

Research output: Contribution to journalArticle

Boiardi, A. ; Silvani, A. ; Milanesi, I. ; Botturi, M. ; Broggi, G. / Primary glial tumor patients treated by combining cis-platin and etoposide. In: Journal of Neuro-Oncology. 1991 ; Vol. 11, No. 2. pp. 165-170.
@article{8775994c72f74471a9ee2dace4aac076,
title = "Primary glial tumor patients treated by combining cis-platin and etoposide",
abstract = "Thirty eight patients with malignant gliomas (27 GBM and 11 AA) were treated with up to 7 cycles of CDDP + VP16 every month after surgery. Chemotherapy was planned as two cycles before and 5 cycles after radiation (42 Gy) using a three times daily fractionation schedule. No severe toxicity was observed. The object of our study was to investigate the antitumor effectiveness by combining CDDP plus VP16 against primary malignant glial tumors. The time to tumor progression (TTP) and survival time (ST) of the GBM patients in the present study were 38.5 and 68,5 weeks respectively. The TTP of the AA patients was 73 weeks and the ST was not calculated as most patients are still alive. By the 18th. month after surgery, 38{\%} of GBM and 74{\%} of AA patients treated with (CDDP + VP16) are still alive. This study demonstrates that the combination of CDDP and VP16 is effective in patients with malignant gliomas.",
keywords = "chemotherapy, cis-platin, etoposide, glioma, survival-time",
author = "A. Boiardi and A. Silvani and I. Milanesi and M. Botturi and G. Broggi",
year = "1991",
doi = "10.1007/BF02390176",
language = "English",
volume = "11",
pages = "165--170",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Springer New York LLC",
number = "2",

}

TY - JOUR

T1 - Primary glial tumor patients treated by combining cis-platin and etoposide

AU - Boiardi, A.

AU - Silvani, A.

AU - Milanesi, I.

AU - Botturi, M.

AU - Broggi, G.

PY - 1991

Y1 - 1991

N2 - Thirty eight patients with malignant gliomas (27 GBM and 11 AA) were treated with up to 7 cycles of CDDP + VP16 every month after surgery. Chemotherapy was planned as two cycles before and 5 cycles after radiation (42 Gy) using a three times daily fractionation schedule. No severe toxicity was observed. The object of our study was to investigate the antitumor effectiveness by combining CDDP plus VP16 against primary malignant glial tumors. The time to tumor progression (TTP) and survival time (ST) of the GBM patients in the present study were 38.5 and 68,5 weeks respectively. The TTP of the AA patients was 73 weeks and the ST was not calculated as most patients are still alive. By the 18th. month after surgery, 38% of GBM and 74% of AA patients treated with (CDDP + VP16) are still alive. This study demonstrates that the combination of CDDP and VP16 is effective in patients with malignant gliomas.

AB - Thirty eight patients with malignant gliomas (27 GBM and 11 AA) were treated with up to 7 cycles of CDDP + VP16 every month after surgery. Chemotherapy was planned as two cycles before and 5 cycles after radiation (42 Gy) using a three times daily fractionation schedule. No severe toxicity was observed. The object of our study was to investigate the antitumor effectiveness by combining CDDP plus VP16 against primary malignant glial tumors. The time to tumor progression (TTP) and survival time (ST) of the GBM patients in the present study were 38.5 and 68,5 weeks respectively. The TTP of the AA patients was 73 weeks and the ST was not calculated as most patients are still alive. By the 18th. month after surgery, 38% of GBM and 74% of AA patients treated with (CDDP + VP16) are still alive. This study demonstrates that the combination of CDDP and VP16 is effective in patients with malignant gliomas.

KW - chemotherapy

KW - cis-platin

KW - etoposide

KW - glioma

KW - survival-time

UR - http://www.scopus.com/inward/record.url?scp=0025883452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025883452&partnerID=8YFLogxK

U2 - 10.1007/BF02390176

DO - 10.1007/BF02390176

M3 - Article

VL - 11

SP - 165

EP - 170

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -